Assignee
LYVGEN BIOPHARMA HOLDINGS LTD
KY·5 granted patents·3 pending applications·14 citations·filing 2016–2022
Top patents by PatentIndex Score
8 records- 0195US11203643B2Humanized anti-CD137 antibodies and uses thereofLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2021·Granted Dec 21, 2021·11 cites·17 claims
- 0282US10913797B2Anti-PD-1 antibodies and therapeutic uses thereofLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2016·Granted Feb 9, 2021·3 cites·23 claims
- 0358US2024218069A1Bi-specific antibodies comprising anti-b7h3 binding moleculesLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2022·Application pending·0 cites
- 0456US2023406950A1Bi-specific antibodies comprising anti-cd137 binding moleculesLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2021·Application pending·0 cites
- 0555US12024560B2Therapeutic agents and methods for enhancing immune responses in tumor microenvironmentLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2018·Granted Jul 2, 2024·0 cites·5 claims
- 0651US11976123B2Anti-CD40 antibodies and uses thereofLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2019·Granted May 7, 2024·0 cites·17 claims
- 0751US2022372155A1Anti-cd40 binding molecules and bi-specific antibodies comprising suchLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2020·Application pending·0 cites
- 0844US11505615B2Anti-CD137 antibodies and uses thereofLYVGEN BIOPHARMA HOLDINGS LTD·Filed 2018·Granted Nov 22, 2022·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when LYVGEN BIOPHARMA HOLDINGS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →